-
Uncategorized2 weeks ago
Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road
Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts.
-
STAT News – Biotech2 weeks agoSTAT+: Merck to buy Terns Pharmaceuticals in $6.7B deal
Merck said Wednesday that it intends to buy Terns Pharmaceuticals, the developer of a promising leukemia treatment, for $6.7 billion. The deal values Terns at $53...
-
Uncategorized2 weeks ago
RA Capital Looks to China for Next Startup To Put on SPAC Track to Nasdaq
While RA Capital Management has yet to commit to a merger plan, it noted that its new blank-check company, Research Alliance III, could target companies abroad,...
-
Uncategorized2 weeks agoTwelve startups to showcase at SLAS Europe 2026
SLAS, the Society of Laboratory Automation and Screening, has introduced the 12 companies selected for the Innovation AveNEW programme at SLAS Europe 2026 Conference and Exhibition,...
-
Endpoints News2 weeks ago
Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex
Maze Therapeutics unveiled positive mid-stage data for its genetic kidney disease drug that could spell major competition for Vertex Pharmaceuticals’ program that has the same target....
-
Fierce Biotech2 weeks ago
After ph. 2 readout, analysts herald ‘best-in-class potential’ for Maze kidney candidate as stock plummets
Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” But many investors were racing...
-
Endpoints News2 weeks ago
Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblix
Merck is looking to further solidify its oncology pipeline via a $6.7 billion cash acquisition of Terns Pharmaceuticals and its investigational treatment for chronic myeloid leukemia....
-
Fierce Biotech2 weeks ago
Takeda targets $1.3B in cost savings in further restructuring
Takeda is setting the stage for a sweeping new round of restructuring, aiming to streamline operations to bankroll upcoming drug launches and late-stage pipeline development.
-
Fierce Biotech2 weeks ago
Endogenex nets $50M to carry intestinal diabetes procedure to the FDA
The fundraising comes after clinical results showed its system met safety goals and led to metabolic improvements in HbA1c, fasting glucose levels and body weight.
-
Uncategorized2 weeks ago
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, notched an FDA approval for a...
